"Long-term collaboration with a global biopharma company will generate around 200 new jobs in the Visp biopark with operations expected to start from end-2022," Lonza said in a statement.
(Reporting by John Miller; editing by Thomas Seythal)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
518.4 CHF | -0.23% | -1.78% | +46.56% |
04-18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
04-18 | Lonza Finance Launches EUR1 Billion 12-Year Euro Bond | DJ |
ZURICH (Reuters) - Lonza on Wednesday announced a deal with an unspecified customer for two new facilities for commercialization of antibody-drug conjugates at its Visp, Switzerland, site as the contract drug maker expands its work with the technology.
"Long-term collaboration with a global biopharma company will generate around 200 new jobs in the Visp biopark with operations expected to start from end-2022," Lonza said in a statement.
(Reporting by John Miller; editing by Thomas Seythal)
1st Jan change | Capi. | |
---|---|---|
+46.56% | 41.42B | |
+22.81% | 47.9B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B | |
+18.47% | 11.64B |